July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Change of Cytokines in Recurred Patients After Ranibizumab Therapy for Branch Retinal Vein Occlusion With Macular Edema
Author Affiliations & Notes
  • Hidetaka Noma
    Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Kanako Yasuda
    Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Masahiko Shimura
    Department of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Hidetaka Noma, None; Kanako Yasuda, None; Masahiko Shimura, None
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4088. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hidetaka Noma, Kanako Yasuda, Masahiko Shimura; Change of Cytokines in Recurred Patients After Ranibizumab Therapy for Branch Retinal Vein Occlusion With Macular Edema. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4088.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the relation of vascular endothelial growth factor (VEGF), as well as other growth factors, soluble VEGF receptors (sVEGFRs), and inflammatory factors, to recurrence of macular edema after anti-VEGF therapy in patients with branch retinal vein occlusion (BRVO).

Methods : This study investigated 17 patients with BRVO who received intravitreal ranibizumab injection (IRI) 3 times within 6 months due to recurrence of macular edema. Aqueous humor samples were obtained from these patients at each recurrence. The levels of sVEGFR-1, sVEGFR-2, VEGF, plancental growth factor (PlGF), platelet-derived growth factor (PDGF)-AA, soluble intercellular adhesion molecule (sICAM)-1, monocyte chemotactic protein (MCP)-1, interleukin (IL)-6, IL-8, IL-12(p70), and IL-13 were measured by the suspension array method. Aqueous flare values were measured with a laser flare meter and central macular thickness (CMT) was examined by optical coherence tomography.

Results : The mean BCVA and CMT improved significantly over time after IRI (P<0.001 and P<0.001, respectively), but there was no significant change of the aqueous flare value at recurrence after IRI compared with baseline. Aqueous humor levels of sVEGFR-1, sVEGFR-2, VEGF, PDGF-AA, MCP-1, and IL-8 decreased significantly over time after IRI (P<0.001, P=0.007, P<0.001, P=0.036, P=0.007, and P<0.001, respectively). In contrast, there were no significant changes of the other 5 factors/cytokines (PlGF, sICAM-1, IL-6, IL-12, and IL-13) at recurrence after IRI compared with baseline.

Conclusions : These findings suggest that persistent inflammation may promote the recurrence of macular edema in BRVO patients, and that adding steroid therapy might be an effective strategy for preventing recurrence.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×